Updated on 15 April 2013
OriGene to acquire SDIX life science assets
Singapore: OriGene Technologies, genome wide product company for research and diagnostic applications, acquired all the assets of life science business of SDIX, a leading provider of biotechnology-based products and services.
Dr Wei-Wu He, chairman and CEO, OriGene, said that, "We anticipate the combination of SDIX with OriGene will enhance our ability to continue to develop the most comprehensive collection of high-quality monoclonal antibodies for key applications both in research and diagnostics fields."
Dr He further said, "SDIX's over 20 years of antibody development and production expertise will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies such as UltraMAB."
OriGene expects the acquisition of SDIX to enhance the capabilities of OriGene to provide immunization strategies for antibody development using full-length mammalian produced protein and genetic immunization technologies to create the highest quality monoclonal antibodies available. OriGene also feels that the deal will expand antibody and IVD reagent product and services capabilities to create significant new commercial opportunities for our existing and new customers including producing UltraMAB for future diagnostic uses.
The transaction will uniquely position OriGene as one of the leaders in antibody development and production to help our customers find the best solutions for their antibody and assay needs. The acquisition is expected to be completed during the second quarter of 2013, subject to the approval of SDIX's shareholders and other customary closing conditions.